Clinical trials of 3-hydroxy-3-methylglutaryl coenzyme A (HMG-CoA) reductase inhibitors or statin therapy demonstrate an improvement in cardiovascular end points and coronary stenosis. However, an improvement in cardiovascular end points and coronary stenosis is incompletely explained by the baseline or treated LDL cholesterol level. The beneficial effects of statins on clinical events may involve nonlipid mechanisms that modify endothelial function, smooth muscle cells, and monocyte-macrophage: vasomotor function, inflammatory responses, and plaque stability. Augmented bioactivity of NO by statin therapy either indirectly by its effect on lipoprotein levels and protection of LDL from oxidation, or directly by effects on NO synthesis and release, might account for enhancement of endothelium-dependent vasodilation. Recent experimental and animal studies have demonstrated that statins dose-dependently decrease smooth muscle cells migration and proliferation, independently of their ability to reduce plasma cholesterol. Moreover, statins are able to reduce the in vitro cholesterol accumulation in macrophages and expression of matrix metalloproteinase, resulting in plaque stability. These effects of statins were completely prevented by the addition of mevalonate and partially by all-trans farnesol and all-trans geranylgeraniol, confirming the specific role of isoprenoid metabolites, probably through prenylated proteins, in regulating these cellular events. Statins have been shown to prevent the activation of monocytes into macrophages, inhibit the production of pro-inflammatory cytokines, C-reactive protein, and cellular adhesion molecules. Statins decrease the adhesion of monocyte to endothelial cells. Accordingly, statins exert their cardiovascular benefits through a direct antiatherogenic properties in the arterial wall, beyond their effects on plasma lipids.
Introduction
compelling evidence of the benefits of cholesterol-lowering. Low-density lipoprotein (LDL) cholesterol levels The acute and chronic manifestations of atherosclerosis serve as the focus of cholesterol treatment guidelines [8, 9] . are increasingly being considered to be a consequence of a However, an improvement in cardiovascular end points chronic inflammatory process [1] . Clinical trials of 3-and coronary stenosis is incompletely explained by the hydroxy-3-methylglutaryl coenzyme A (HMG-CoA) rebaseline or treated LDL cholesterol level [2] [3] [4] [5] [6] [7] . The ductase inhibitors or statin therapy demonstrate an imrelationship between baseline and treated LDL cholesterol provement in cardiovascular end points and coronary levels and cardiovascular end points has been evaluated in stenosis [2] [3] [4] [5] [6] [7] . This database of trials, which now consists several clinical trials [2, 4, 6] . In the Scandinavian Simvasof more than 30 000 patients from at least three continents tatin Survival Study, survivors of coronary artery disease and tests three different statins (lovastatin, pravastatin, and mostly with highly elevated LDL-C levels reported that simvastatin), is consistent in its positive results. In parmajor coronary events were reduced by a similar amount ticular, clinical trials in the 1980s and 1990s have provided regardless of the baseline LDL cholesterol level [2] . The West of Scotland Coronary Prevention Study (WOSCOPS) included men who were without myocardial infarction but at high risk because of their LDL-C levels and other (NO) plays a pivotal role in maintaining vascular health factors [4] . This study evaluated the relationship between and protecting from vascular injury under these pathologion-treatment LDL-C levels or total cholesterol change and cal conditions. coronary heart disease (CHD) risk using the Framingham Thus, as the role of endothelium, smooth muscle cell CHD-risk model. The CHD event rate in pravastatinand monocyte-macrophage is important in the pathogenesis treated patients was not related to the magnitude of LDL of atherosclerosis and CHD, we will review the effects of cholesterol level lowering when the LDL cholesterol level statins on vascular wall as plausible mechanisms to prevent reduction ranged from 19 to 54% [4] . The Framingham or regress atherosclerosis and CHD. model accurately predicted the CHD event risk rate in the placebo group but underestimated the CHD risk reduction in the pravastatin therapy group by 35%.
2. Endothelial dysfunction, atherosclerosis, and Indeed, elevated LDL cholesterol levels identify less coronary artery disease than one half of individuals who will die from CHD [10] . The LDL cholesterol concentrations had a sensitivity of Several groups have shown that epicardial coronary 47% in predicting 10-year CHD death rates in the Lipid arteries in patients with coronary artery disease constrict Research Clinics Prevalence Study [11] . The revised both at sites of angiographically obstructive atherosclerotic National Cholesterol Education Program (NCEPII) guidedisease and at sites of plaquing in response to acetyllines [9] that stratify risk by LDL cholesterol levels and choline [22, 23] . [24] . In hypercholesterolemic subjects, Nlowering properties [16, 17] . This in vitro inhibition was monomethyl-L-arginine has similar effect on basal forearm G completely prevented by the addition of mevalonate and flow compared to normals. However, the effect of Npartially by all-trans farnesol and all-trans geranylgeraniol monomethyl-L-arginine on the forearm flow response to [17] [18] [19] . These results suggest that statins exert a direct acetylcholine was reduced compared with normocholesantiatherosclerotic effect in the arterial wall, beyond their terolemic subjects, suggesting preserved release of NO in effects on plasma lipids. the basal state but reduced NO activity during endothelial Therefore, recent studies suggest that the beneficial stimulation [25] . effects of statins on clinical events may involve nonlipid These observations suggest that endothelial dysfunction mechanisms that affect endothelial function, smooth musof epicardial coronary arteries precedes development of cle cells, and monocyte-macrophage: vasomotor function, atherosclerotic disease that is either angiographically apinflammatory responses, and plaque stability [12, 20, 21] . parent or of sufficient obstructive severity to cause These nonlipid mechanisms of statins may contribute to myocardial ischemia and angina pectoris. In these regards, the cardiovascular event reduction and explain the early serial angiographic studies performed prior to and followclinical benefit in these clinical trials [4] [5] [6] .
ing an acute myocardial infarction indicate that the underPatients with CHD or risk factors for CHD including lying plaque responsible for unstable angina and myocarhypercholesterolemia, systemic hypertension, smoking, dial infarction was usually less than 50% narrowed prior to diabetes, or estrogen deficiency, hyperhomocysteinemia, the acute event [26, 27] . Indeed, a recent angiographic and the aging process itself, have been associated with study suggests that the positive correlation between the impaired functions of the endothelium. The vessel wall in number of severely diseased arteries and coronary mortalithese conditions may promote inflammation, oxidation of ty may not just be related to the number of arteries with lipoproteins, smooth muscle proliferation, extracellular 70% or greater stenosis, but may be also tied in with the matrix deposition or lysis, accumulation of lipid-rich amount of minor plaque disease in other vessels [28] . It is material, platelet activation, and thrombus formation. All possible that patients with multivessel disease perhaps of these consequences of endothelial dysfunction may have a higher mortality than those with single vessel contribute to development and clinical expression of disease because they have more non-stenotic or mildly atherosclerosis. In other words, abnormalities in the funcstenotic plaques that are sites for future coronary events. tion of the endothelium are therefore likely to play an These observations and the finding that the progression to important role in the pathogenesis of CHD. Nitric oxide an acute infarction is not proportionately related to the prior severity of the coronary stenosis [26, 27] has been endothelial dysfunction and reduced NO bioactivity may driving the search for other mechanisms. An increasing be important in the initiation, progression, and clinical body of evidence is now highlighting a potentially imexpression of atherosclerosis. portant player in atherosclerosis and CHD, the endothelium.
4. Infection, inflammation and endothelial dysfunction 3. Mechanisms and consequences of endothelial There has been also considerable interest in the links dysfunction in hypercholesterolemia between chronic infections and the slow process of atherogenesis [42] . Deaths from cardiovascular disease Endothelial cells in hypercholesterolemic animal models increase during and after epidemics of influenza [43] . This of atherosclerosis may also produce increased quantities of occurs not only in the frail elderly but also in previously highly reactive molecules such as superoxide anion [29] well middle-aged men. Bacterial infections also seem to be and oxidative stress product, 8-epi-prostaglandin F [30] . associated with increased risk [44] . Together, these ob2a
What is unclear is whether the actual synthesis of NO by servations suggest that infection or acute systemic inflamthe dysfunctional endothelium in hypercholesterolemia is mation might temporarily increase the risk of an acute increased or decreased. In support of the possibility of cardiovascular event. It seems unlikely that this increased increased NO formation, the release of nitrogen oxides is risk is due to acute changes in the overall bulk of increased from atherosclerotic rabbit aorta compared with atheroma, but rather that the pre-existing atheroma becontrol tissue [31] . LDL added to endothelial cells [32] or comes more likely to support thrombosis and vasospasm. macrophages [33] in culture stimulates the release of Consistent with this idea, the transition from stable to nitrogen oxides (especially peroxynitrite). On the other unstable angina appears to be associated with a systemic hands, oxidized LDL has been shown to stimulate the inflammatory response [45] , and markers of acute inflamtranscription and synthesis of constitutive NO synthase mation (including cytokines, C-reactive protein and white [34] . In contrary, some studies demonstrated that oxidized cell count) are all related at increased cardiovascular risk LDL inhibited the transcription and synthesis of inducible [45, 46] . Interestingly, instability of atheroma is not always NO synthase [35, 36] . However, increased expression of confined to one plaque, but can occur at multiple sites in the inducible form of NO, capable of synthesizing even different vascular beds, again suggesting that the underlylarger quantities of NO than the constitutive form of this ing process may be systemic rather than local in origin enzyme, has been detected in human atherosclerotic [47] . plaques [37] . Thus, endothelial cells in hypercholesHow might inflammation or infection alter the risk terolemia and atherosclerosis may synthesize greater than associated with atheroma? Bacterial endotoxin, or certain normal quantities of NO, but increased NO formation may pro-inflammatory cytokines, may also inhibit the ability of be with rapid oxidative inactivation or conversion to toxic endothelial cells to generate NO and / or certain vasodilator nitrogen oxides due to the excess accumulation of superoxanti-aggregatory prostanoids [48, 49] . These effects have ide anions and free radical molecules.
been observed in whole animals [48] and in experimental In patients with hypercholesterolemia and in patients models in healthy volunteers [49] . In healthy volunteers, with coronary atherosclerosis, coronary and systemic areven a very brief exposure to endotoxin or certain cytoteries may constrict during exercise [38] or with mental kines impairs endothelium-dependent relaxation for many stress [39] , likely due to loss of dilator regulation by the days, and the degree of the impairment is considerably coronary endothelium as consequence of diminished regreater than that produced by chronic risk factors. This lease of NO to the visceral smooth muscle, whether by effect has been termed endothelial 'stunning' [49]. The decreased synthesis or excess degradation, and enhanced experimental and epidemiological data together suggest vascular sensitivity to constrictor stimuli such as norepithat endothelial dysfunction following acute infection or nephrine [39] . Reduced NO could also stimulate the inflammation may indeed provide a transient risk factor for synthesis and releases of endothelin resulting in enhanced myocardial infarction and unstable angina, which might vasoconstrictor tone, promote the release and activity of promote abnormal vascular behavior and be amenable at growth factors resulting in smooth muscle hyperplasia and pharmacological intervention. migration into the intima, and enhance the synthesis and Indeed, several studies now report the potential benefit release of proinflammatory cytokines. Additionally, rein treating patients with known ischemic heart disease with duced NO could promote platelet attachment and release of antibiotics and report a significant reduction in the incigrowth factors in the vessel wall. Reducing NO availability dence of unstable angina and myocardial infarction [50] . In through a synthase inhibitor increases the development of contrast, Ridker et al. investigated the association between atherosclerosis, whereas increasing its availability through Chlamydia pneumoniae [51] or herpes simplex virus or the administration of L-arginine decreases its development, cytomegalovirus [52] IgG seropositivity and risks of future at least transiently [40, 41] . All of these consequences of myocardial infarction among apparently healthy middle-aged men in a prospective cohort study. They found no evidence of association between both. Anderson et al.
[53] performed a randomized secondary prevention trial of azithromycin in patients with coronary artery disease and serological evidence for Chlamydia pneumoniae infection. In patients with coronary artery disease positive for Chlamydia pneumoniae antibodies, global tests of four markers of inflammation (C-reactive protein, interleukin-1 and 6, TNF-a) improved at 6 months with azithromycin. However, there were no differences in antibody titers and clinical events. arteries of patients with atherosclerosis, cholesterol lowering with pravastatin and lovastatin improves endothelial function as evidenced by limiting acetylcholine-induced with marginal significance serum nitrate / nitrite levels by vasoconstriction [54, 55] . The LDL cholesterol-lowering 5637 and 6630%, respectively. Conjugated estrogen therapy with simvastatin improves peripheral NO-mediated insignificantly increased serum nitrate / nitrite levels by vascular relaxation [56] . The improved coronary blood 5638% (Fig. 2) . Reduction in luminal release of NO after flow and vasodilator response with statin therapy alleviate statin therapy may indicate reduced synthesis of NO transient ischemia in patients with stable angina pectoris required for endothelial homeostasis as a consequence of [57] and improve myocardial perfusion [58] . Statin therapy reduced degradation of NO by oxidized lipoproteins and may contribute to the observed clinical benefits of these free radical molecules from the endothelium and from agents through ameliorating endothelial dysfunction.
Biological effects of statins
inflammatory cells [64] . In our recent studies [65, 66] , this Goode and Heagerty [59] isolated small arteries from speculation was confirmed. subcutaneous biopsies performed in 18 hypercholesAugmented bioactivity of NO by statin therapy either terolemic patients and demonstrated impaired dilator reindirectly by its effect on lipoprotein levels and protection sponses to acetylcholine. Ten of these patients underwent of LDL from oxidation, or directly by effects on NO repeat biopsies about 10 months after lipid-lowering synthesis and release, might account not only for enhancetherapy, which reduced LDL levels by 56%. Significant improvement in vasodilator responses to acetylcholine was observed in these patients compared with their baseline values. Recently, we randomly assigned 28 women to conjugated estrogen 0.625 mg, simvastatin 10 mg, and their combination per day, with each treatment period lasting 6 weeks [60] . Brachial artery dilator responsiveness to hyperemia and to nitroglycerin was measured by ultrasonography. Compared with respective baseline values, simvastatin alone significantly reduced LDL cholesterol by 25%. Simvastatin improved flow-mediated dilation from 4.3 to 10.0%, compared with respective baseline values (Fig. 1) . Some studies have demonstrated that fluvastatin [61] or LDL apheresis [62] improved endothelium-dependent vasodilatation in hypercholesterolemic patients, respectively. ment of endothelium-dependent vasodilation but also for geranylgeranylation of RhoGTPase [18, 19] . In this regard, much of the anti-atherogenic effects of statin by inhibition Raiteri et al. [17] demonstrated that statins (simvastatin, of platelet aggregation, platelet and inflammatory cell cerivastatin, fluvastatin) dose-dependently decreased attachment to the endothelial surface of the vessel wall, smooth muscle cell proliferation, independently of their and release of factors that stimulate growth and migration ability to reduce plasma cholesterol. This effect was of smooth muscle cells within the vessel wall [67] .
prevented by mevalonate, all-trans farnesol and all-trans Besides lipid-lowering effects of statins, one of the geranylgeraniol, precursors of protein prenyl groups. Furimportant mechanisms regarding improvement of vasother, Stark and his colleagues [18] showed that motor function may be antioxidant effects of statins, which geranylgeranylated proteins were required for growth and enhances NO bioactivity by preventing NO degradation protected smooth muscle cell against apoptosis, and Laufs kip1 from free radical molecules. In this regard, Kleinveld et al. et al. [19] reported that the down-regulation of p27 by [68] reported that 18 weeks of pravastatin or simvastatin Rho GTPase mediated platelet-derived growth factor-indecreased LDL cholesterol levels by 36% and significantly duced smooth muscle cell DNA synthesis, and statins reduced the rate and extent of copper-catalyzed LDL attenuated smooth muscle cell proliferation by preventing kip1 oxidation. LDL particles after therapy were changed in Rho GTPase-induced down-regulation of p27 . These composition to contain less lipid relative to protein, data obtained in vitro have been confirmed in vivo in possibly rendering the particle less susceptible to oxidation experimental models of smooth muscle cell activation [69] . Indeed, Giroux et al. [70] reported the simvastatin [16, 77] . The inhibitory effect of lipophilic statins on diminished superoxide anion formation and LDL oxidation smooth muscle cell proliferation has been recently shown by human macrophages in tissue culture and Giroma et al.
in different models of proliferating cells such as cultured [71] recently demonstrated that simvastatin decreased arterial myocytes [77] and rapidly proliferating carotid and aldehyde production derived from lipoprotein oxidation, femoral intimal lesions in rabbits [16] . Interestingly, the suggesting simvastatin as an antioxidant in lipoprotein treatment with the various statins did not modify rabbit particles. However, Palomaki et al. [72] reported that plasma cholesterol concentrations. Finally, ex vivo studies lovastatin decreased the depletion time of reduced ashowed that sera from fluvastatin-treated patients interfered tocopherol in metal ion-independent oxidation by 44% and with smooth muscle cell proliferation [78, 79] . Thus, statins shortened the lag time of conjugated-diene formation in exert a direct antiatherosclerotic effect in the arterial wall, metal ion-dependent oxidation by 7%, suggesting each beyond their effects on plasma lipids. statin may act differently regarding an antioxidant effect.
Of interest, some studies have shown that LDL induces 5.3. Effects of statins on inflammation angiotensin II type 1 receptor upregulation in isolated vascular smooth muscle cells and that hypercholesAn early step in atherogenesis involves monocyte terolemic rabbits display an enhanced vascular expression adhesion to the endothelium and penetration into the of angiotensin II type 1 receptors [73, 74] . Angiotensin II subendothelial space. Oxidized LDL binds to the type 1 receptor overexpression may account for enhanced scavenger cell receptor on monocyte-derived macrophages release of free radicals and increased vasoconstriction and and contributes to foam cell formation. Inflammatory cell proliferation. Indeed, angiotensin II type 1 receptor cytokines secreted by macrophages and T lymphocytes can expression was significantly enhanced in hypercholesmodify endothelial function, smooth muscle cell proliferterolemic individuals [75] . Further, lipid-lowering treatation, collagen degradation, and thrombosis [80] . ment with statins reversed the elevated blood pressure Scalia et al. [81] clearly demonstrated the role of Presponse to angiotensin II infusion and downregulated selectin, intercellular adhesion molecule (ICAM-1), and angiotensin II type 1 receptor density [75] . In another vascular cell adhesion molecule (VCAM-1) in leukocytestudy, cholesterol level reduction achieved with lovastatin endothelium interaction during the early stages of hyor pravastatin was associated with an additional significant percholesterolemia in the rabbit model. They observed reduction in diastolic blood pressure in patients taking upregulation of the endothelial cell adhesion molecules enalapril or lisinopril [76] .
immunohistochemically in the intestinal microvascular endothelium of hypercholesterol diet-fed rabbits. Paster-5.2. Effects of statins on smooth muscle cells kamp et al.
[82] investigated the prevalence and distribution (local versus general) of inflammatory cells in Since mevalonate, the product of the enzyme reaction, is nonruptured atherosclerotic plaques. Inflammation of the the precursor of numerous metabolites, statins have the cap and shoulder of the plaque is a common feature, potential to result in pleiotropic effects [13, 14] . A key locally observed, in atherosclerotic femoral and coronary event in the atherogenesis is the migration and proliferarteries. Cholesterol level lowering in experimental models ation of arterial smooth muscle cells in the arterial wall was accompanied by a reduction of inflammatory cells [1, 42] . Smooth muscle cell proliferation involves the within atherosclerotic plaque [83, 84] . mevalonate pathway [17] mainly via the prenylation and Subjects with hypercholesterolemia have increased adhesiveness of isolated monocytes to fixed endothelial Cholesterol and Recurrent Events trial [95] . These effects cells in vitro, and this response is diminished with lovaswere present even though those with and without elevated tatin and simvastatin [83] . In contrast, this group demonlevels of C-reactive protein had virtually identical baseline strated that lovastatin enhanced Mono Mac 6 adhesiveness lipid levels. Further, regarding the long-term effects of to human umbilical vein endothelial cells by the increased pravastatin on C-reactive protein, randomization to pravasCD11b and CD14 expression [85] . Hypercholesterolemic tatin resulted in significant reductions of C-reactive protein rats treated with fluvastatin have significantly attenuated that were not related to the magnitude of lipid alterations leukocyte-adherence responses to platelet activation factor observed, in contrast to survivors of myocardial infarction and leukotriene B [84] . Indeed, cellular interaction beon standard therapy plus placebo showing increasing C-4 tween monocytes and endothelial cells was inhibited by reactive protein levels over 5 years of follow-up [96] . fluvastatin, mediated via reducing the expression of These data strongly support the potential for nonlipid lymphocyte function associated antigen-1 and ICAM-1, effects of statins. particularly in the side of monocyte [86] . Of interest, the inhibitory effects of fluvastatin on the expression of 5.4. Effects of statins on plaque stability adhesion molecules were completely reversed by the addition of mevalonate. This effect of statins may be Collagen is the main component of fibrous caps responmediated through decreasing the expression of LDL resible for their tensile strength. Macrophages are capable of ceptor on monocytes [87] . In a rabbit atherosclerosis degrading extracellular matrix by phagocytosis or by model, atorvastatin abolished arterial macrophage infiltrasecreting proteolytic enzymes, in particular a family of tion and monocyte chemoattractant protein-1 in the neoinmetalloproteinases that may weaken the fibrous cap, tima and in the media [88] . Simultaneously, atorvastatin predisposing its rupture. Lipids in the atheroma not only downregulated monocyte chemoattractant protein-1 exprescreate mechanical instability, but also biologically active sion and NF-kB activity induced by tumor necrosis factor lipids participate in promoting oxidative stress and ina in cultured vascular smooth muscle cell. This study flammatory responses such as monocyte migration. Lipidconcluded that atorvastatin diminished the neointimal lowering may therefore influence the matrix degradation inflammation and this could contribute to the stabilization cascade that appears most active in macrophage-rich areas of the atherosclerotic plaque.
of the atheroma, as well as promote mechanical stability With regard to a clinical study, Abe et al. [89] observed within the plaque. significantly increased levels of soluble ICAM-1 and Statins inhibit cholesterol ester accumulation in mono-VCAM-1 in patients with hypertriglyceridemia and low cyte-derived macrophages either by reducing the availabilihigh-density lipoprotein cholesterol. Rohde et al. [90] ty of free cholesterol toward the enzyme acyl-coenzyme A recently demonstrated that age-adjusted soluble ICAM-1 cholesterol acyltransferase by trapping it in phospholipidand VCAM-1 levels increased in a stepwise fashion across containing pools, or by inhibiting LDL endocytosis related common carotid intima-media thickness tertiles. This study to reduced synthesis of mevalonate or mevalonate bysupports the hypothesis that systemic inflammation may products required for cholesterol esterification [13] . The have a role in atherosclerotic lesion development. In addition of mevalonate or all-trans geranylgeraniol fully patients with cardiac transplants, pravastatin may suppress prevented the inhibitory effect of fluvastatin and simvasthe inflammatory response and inhibit natural killer cell tatin, suggesting that a non-sterol derivatives of mevaloactivity in cyclosporin-treated patients [91] . In our current nate is involved in the endocytosis and esterification of study, simvastatin alone did not significantly change exogenous cholesterol delivered to macrophages by modisoluble E-selectin, ICAM-1, and VCAM-1 levels [60] . Of fied LDL [13] . Interestingly, the efficacy of fluvastatin in interest, simvastatin significantly lowered serum inhibiting cholesterol esterification was greater in cholesinterleukin-6 levels from 2.2061.30 to 1.8860.97 ng / ml terol-loaded than in normal cells, suggesting a possible in our study. Indeed, lovastatin suppressed interleukin-6 or specific and more pronounced effect on the atherogenous -8, not -1b, by activated monocytic cells in vitro [92] . The arterial wall. Kempen et al. [97] reported a dose-dependent addition of mevalonate prevented the attenuation of inhibition of cholesterol accumulation in macrophages that interleukin-8 production by lovastatin.
was greater with lovastatin and simvastatin than with C-reactive protein is a marker of inflammation [93] .
pravastatin. Lowering blood LDL cholesterol levels may Strandberg et al. [94] demonstrated that simvastatin or facilitate plaque stability either through a reduction in size atorvastatin lowered C-reactive protein in hyperlipidemic [98] or by an alteration of the physiochemical properties of coronary patients. Indeed, with respect to the clinical lipid cores [99] . Hydrolysis of liquid cholesterol esters to benefits of statins on C-reactive protein, the association solid cholesterol crystal can yield firmer plaques. between C-reactive protein and subsequent risk of reIn this regard, Aikawa et al. [100] demonstrated that current coronary events was significant among those lipid lowering favored accumulation of mature smooth randomized to placebo, but was attenuated and no longer muscle cells in the atherosclerotic intima in association significant among those assigned to pravastatin in the with reduced levels of platelet-derived growth factor-B expression. They also showed that intimal smooth muscle (Chief, Division of Cardiology, Gachon Medical School, cells in the low cholesterol group displayed reduced Inchon, Korea). expression of matrix metalloproteinases-3 and -9 compared with the control and high cholesterol groups. In another study, Aikawa et al. [101] demonstrated that the lipidReferences lowering group showed progressive reduction in both macrophage content and matrix metalloproteinase-1 im- potentials [103] . Similar data were obtained with simvas- consistent with plaque stability than those of monkeys not 
